Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant
This study is testing different combinations of targeted medicines and chemotherapy after radiation therapy for children and young adults with newly diagnosed, fast-growing brain tumors. Doctors want to see if these specific drug combinations can help slow down tumor growth and help patients live longer.
This study is for patients between 12 months and 39 years old who have been newly diagnosed with certain types of fast-growing brain or spinal cord tumors, such as high-grade glioma or DIPG. Their tumor tissue must be confirmed through a biopsy or surgery, and patients must meet specific health and birth control requirements.
Participants will receive a combination of specially chosen medications, such as ribociclib paired with either everolimus or temozolomide, depending on their specific tumor type and genetic markers. The medical team will closely monitor patients during and after treatment to check their health and how well the therapy is working.
The study is currently open and recruiting patients at medical centers in locations including Aurora, Colorado; Washington D.C.; and Chicago, Illinois. Your care team can help you find the closest participating location.
- 1Tests medication combinations for children and young adults with specific fast-growing brain tumors.
- 2Aims to see if the treatments can help prolong life and control tumor growth.
- 3Currently recruiting patients at select medical centers in the United States.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.